Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
about
PEGylation of Interferon-β-1aCutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic reviewNew and emerging disease modifying therapies for multiple sclerosisCost-Effectiveness of Disease-Modifying Therapies in Multiple SclerosisSodium channel blockers for neuroprotection in multiple sclerosisImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisType I interferons for induction of remission in ulcerative colitisSodium channel blockers for neuroprotection in multiple sclerosisAlemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosisIntravenous immunoglobulin to prevent relapses during pregnancy and postpartum in multiple sclerosisImmunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathyImmunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisImmunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathyInterferon Beta for Primary Progressive Multiple SclerosisInterferon Beta for Primary Progressive Multiple SclerosisType I interferons for induction of remission in ulcerative colitisRecombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosisType I interferons for induction of remission in ulcerative colitisRecombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosisMagnetic resonance imaging as a surrogate outcome for multiple sclerosis relapsesSerum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1aThe Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-AnalysisDisease-modifying treatments for multiple sclerosis - a review of approved medicationsOptimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosisTreatment strategies for multiple sclerosis: When to start, when to change, when to stop?Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysisRegression to the mean and predictors of MRI disease activity in RRMS placebo cohorts--is there a place for baseline-to-treatment studies in MS?Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple SclerosisComprehension of confidence intervals - development and piloting of patient information materials for people with multiple sclerosis: qualitative study and pilot randomised controlled trial.Antidrug Antibodies: B Cell Immunity Against TherapyThe mechanism of action of interferon-β in relapsing multiple sclerosisA type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosisTreatment of cognitive impairment in patients with multiple sclerosisNatalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosisCladribine tablets for the treatment of relapsing-remitting multiple sclerosisMultiparameter phospho-flow analysis of lymphocytes in early rheumatoid arthritis: implications for diagnosis and monitoring drug therapyEstablishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MSThe Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platformRisk Factors for Poor Adherence to Betaferon® Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated SyndromeLong-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis
P2860
Q22241420-F2A7E28E-F8E7-4569-95D4-64E008796466Q22241795-0A879FC6-75F9-49F2-9544-2441C76B1D91Q22242305-7D5CDA0A-A3BC-4DFC-9A5A-E6C03BC0C70AQ22252598-CBA20B66-38E3-4710-AF33-5888604BD33CQ24186448-B055AFED-1710-4AD9-9497-CB95483FE256Q24187126-43B15AC4-B493-40E0-9E72-4468367A9733Q24187202-B912FCD8-E2CA-4C0E-8E9C-A6DE2D6D988BQ24200461-97A62753-F8F6-4CE3-8F4D-C193079758A0Q24200823-BECB5B2F-FC3B-4D73-ADCF-E041B7E29AE7Q24201599-DA82E177-D553-4F72-AFA5-A07CA7CB5A6BQ24201954-41758BFF-8A1D-4CE2-80D3-E5A6E117C218Q24202108-4A9E3AA2-5F21-4913-BA2B-E56B96DBE0D3Q24236599-EBB97ECA-3E6A-4FAE-ACB9-FACDA66F577CQ24240620-35F42CD9-2DE2-4F4F-BF9F-A6D49BB826DBQ24241541-3303C004-A814-4ED9-8F84-47CCC46B6E6AQ24241993-E021DF02-AA16-49AB-8CD2-A99163C46340Q24243043-779BECA2-CC1D-4B07-960C-D2E931E91FC4Q24243201-BAC3F9F4-20CF-47D2-8F86-935F485AD509Q24244748-CD72A717-BE94-45EF-AC59-50A18A28206DQ24288978-C5E72669-AC2F-4A6B-889D-52B6043AA109Q24805642-C778A16B-82B5-4BF9-987E-6A656C3B4814Q26773978-FF8A7CA8-2034-429C-82E2-0E53E5E687A8Q26777329-4F36BACE-C1B7-4C02-BE47-D0C5444E9CF5Q26777686-B3022D79-FA19-41D5-9E10-FF1C1ED1FCCAQ26798434-EC171215-DBC1-45E3-979D-C86BC83F2179Q26828463-868C3C01-D657-4BFC-A1EB-E618E64BDE78Q26998513-9F324072-E452-4C33-AA0B-0EEA39C3098EQ27000269-6E640F70-4E63-4F4B-A780-67C709F184C2Q27307622-7D3A76B6-39BC-43FD-AB9E-4ED90EB27B32Q28082303-CA9A98B3-9B9D-46D8-9365-58025B43491AQ28239752-9AF0204C-6AFF-43FD-9DE2-F7BE77CD6A88Q28257957-4B80A78A-479B-45C3-947D-5165E24296BEQ28272736-C333331D-FAEE-4E15-BC3E-C2573D0E0501Q28277470-A4C25F39-FC53-4A37-BA7A-9B43A9147FDBQ28281816-0F48EB9D-B243-4942-B95C-2F807248449FQ28475972-C4704682-4958-43BE-A045-737313C78971Q28478190-22FEDEAE-865D-4913-AA30-829437779C43Q28488248-6A65179C-588A-467D-90A2-1C03281AC2CCQ28554434-AA8F1BB8-9091-4BEC-B637-3E9DEB7CA269Q28597830-32B0F5D2-0F08-4A15-861A-D966C7ACFDF3
P2860
Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
description
article publié dans la revue scientifique The Lancet
@fr
im November 1998 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published in The Lancet
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 1998
@uk
ശാസ്ത്രപ്രബന്ധം
@ml
name
Randomised double-blind placeb ...... g/remitting multiple sclerosis
@en
Randomised double-blind placeb ...... g/remitting multiple sclerosis
@nl
type
label
Randomised double-blind placeb ...... g/remitting multiple sclerosis
@en
Randomised double-blind placeb ...... g/remitting multiple sclerosis
@nl
prefLabel
Randomised double-blind placeb ...... g/remitting multiple sclerosis
@en
Randomised double-blind placeb ...... g/remitting multiple sclerosis
@nl
P921
P1433
P1476
Randomised double-blind placeb ...... g/remitting multiple sclerosis
@en
P2093
George C Ebers
P304
P356
10.1016/S0140-6736(98)03334-0
P407
P577
1998-11-01T00:00:00Z